Home・Aandelen Lijst・Compugen Ltd

Compugen Ltd

Open

2.15 2.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.08

Max

2.13

Belangrijke statistieken
By Trading Economics
Inkomsten	-65M -7.7M
Verkoop	-65M 2.2M
K/W Sectorgemiddelde	5.447 50.958
EPS	-0.08
Winstmarge	-352.436
Werknemers	75
EBITDA	-64M -7.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+123.44% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-75M 196M
Vorige openingsprijs	-0.72
Vorige sluitingsprijs	2.15

Compugen Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 jun 2026, 23:51 UTC

Bitcoin dips while Ethereum rises amid investor caution over stock market leverage and upcoming AI earnings reports.

28 jun 2026, 23:51 UTC

Japan's retail sales data reveals consumer spending trends amid rising concerns over stock market leverage and volatility, as investors brace for upcoming U.S. Non-Farm Payrolls report.

28 jun 2026, 23:51 UTC

Bitcoin dips while Ethereum rises amid investor concerns over high leverage and volatility in equity markets, with key U.S. economic data expected to influence market dynamics.

28 jun 2026, 23:51 UTC

Bitcoin dips as Ethereum rises amid concerns over high leverage in stock markets and anticipation of Meta's earnings report, with key economic data releases on July 2 expected to impact Federal Reserve policy.

28 jun 2026, 23:51 UTC

ECB Forum on Central Banking Set for June 29, 2026: Focus on Monetary Policy and Interest Rates Amid Economic Uncertainties.

28 jun 2026, 23:51 UTC

Macro News

Bitcoin is lower as geopolitical tensions rise and South Korean stocks decline. It is currently about 5.32% below its 20-day moving average.

28 jun 2026, 23:41 UTC

Japan's Retail Sales Expected to Rise 3.2% in May, Boosting Investor Confidence Amid Global Market Concerns

28 jun 2026, 23:41 UTC

Avalanche is higher today, continuing its modest gain since Saturday's close. The price has fluctuated within a narrow range during the session.

28 jun 2026, 23:41 UTC

The FTSE 100 Index is lower after market hours, reflecting cautious investor sentiment amid rising concerns over high leverage and increased equity financing costs.

28 jun 2026, 23:32 UTC

Macro News

Correlated Moves

Ethereum is trading lower amid heightened geopolitical tensions and stock market volatility. Earlier in the session, it rebounded from a session high.

28 jun 2026, 23:22 UTC

Market Awaits BoE Governor Bailey's Speech on Interest Rates Amid AI-Driven Financial Stability Concerns.

28 jun 2026, 23:22 UTC

Market Awaits U.S. Average Hourly Earnings Data Amid Wage Legislation Debates and AI Sector Concerns Impacting Federal Reserve Policy.

28 jun 2026, 23:22 UTC

U.S. Labor Force Participation Rate Report Set for July 2, Amid Employee Dissatisfaction and Minimum Wage Legislation Debates

28 jun 2026, 23:22 UTC

Investors Brace for Insights on Interest Rates as BoC Governor Macklem's Speech Approaches Amid Economic Challenges in Canada

28 jun 2026, 23:22 UTC

U.S. Unemployment Rate Expected to Hold Steady at 4.3% Ahead of July 2 Release Amid Employee Dissatisfaction and Potential Minimum Wage Legislation

28 jun 2026, 23:22 UTC

U.S. Non Farm Payrolls Report on July 2 Forecasts 114K Job Additions Amid Cautious Market Sentiment and Legislative Changes Impacting Labor Dynamics.

28 jun 2026, 23:22 UTC

Market Awaits June 2026 Average Hourly Earnings Data Amidst Wage Growth Concerns and Legislative Push for Minimum Wage Increase.

28 jun 2026, 23:12 UTC

Mexico's Consumer Confidence Index set for July 3, 2026 release amid declining sentiment and cautious market expectations.

28 jun 2026, 23:11 UTC

GBP/CHF remains roughly flat during after-market hours, trading within a routine range since Friday's close amid concerns over high leverage in the stock market.

28 jun 2026, 23:11 UTC

SGD/CHF is trading roughly flat in after-market hours, remaining near the upper end of its one-month range amid broader market volatility concerns.

28 jun 2026, 23:11 UTC

Correlated Moves

USD/SEK remains roughly flat in after-market hours amid concerns about high leverage in the stock market and its impact on volatility.

28 jun 2026, 23:11 UTC

Correlated Moves

CHF/HKD trading remains roughly flat during after-market hours amid concerns over high stock market leverage and increased volatility in equity financing costs.

28 jun 2026, 23:01 UTC

Gold and silver prices are trading higher during the ongoing session, remaining above their 20-day moving average and near the upper end of their one-month range.

28 jun 2026, 23:01 UTC

Correlated Moves

Silver/CHF is lower today, following a decline from earlier highs. The asset trades below its 20-day moving average amid shifting market sentiment and increased volatility.

28 jun 2026, 23:01 UTC

Correlated Moves

Silver/GBP is lower today, reflecting declines in correlated assets like gold. Prices have fluctuated notably, currently near the lower end of its one-month range.

28 jun 2026, 23:01 UTC

Macro News

US 10Y Treasury Bond Index advances amid escalating Middle East tensions and lower oil prices, reflecting cautious investor sentiment near the upper trading range.

28 jun 2026, 23:01 UTC

The US 5Y Treasury Bond Index is trading higher, reflecting increased activity. It remains near the upper end of its one-month trading range.

28 jun 2026, 23:01 UTC

Macro News

Tensions between the U.S. and Iran have reportedly eased, potentially influencing global oil markets. The US 2Y Treasury Bond Index is trading roughly flat.

28 jun 2026, 23:01 UTC

Correlated Moves

Silver/SGD is trading lower, reflecting a challenging market environment and notable volatility. The asset remains significantly below its 20-day moving average.

28 jun 2026, 23:01 UTC

Correlated Moves

Silver/JPY is lower today, reflecting notable volatility and trading near the lower end of its one-month range. The asset is approximately 9.98% below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Compugen Ltd Prognose

Koersdoel

By TipRanks

123.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.67 USD 123.44%

Hoogste 5 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compugen Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Compugen Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.